Theracryf annual ebitda
2022
2023
2024
2025
Theracryf EBITDA Growth & History (TCF)
Theracryf's calculated EBITDA was −£2.0M for fiscal 2025.
View full Theracryf company overviewTheracryf annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | −£2.0M | £1.5M | — |
| 2024 | 2024-03-31 | −£3.5M | £1.5M | — |
| 2023 | 2023-03-31 | −£5.1M | −£1.9M | — |
| 2022 | 2022-03-31 | −£3.2M | — | — |
Theracryf ebitda trends
Between the periods ended 2022-03-31 and 2025-03-31, Theracryf's ebitda increased from −£3.2M to −£2.0M, a change of £1.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Theracryf source filings ↗Community posts
TheraCryf approves £1.05m capital raise and share-capital reorganisation
TheraCryf confirmed on 7 September 2026 that shareholders approved its approximately £1.05m gross capital raise and the related subdivision of share capital. Shares and dates The placing and subscription will issue 583,333,328 new ordinary ...